GleamWall
中文EN

ENTA ENANTA PHARMACEUTICALS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1177648 · Fiscal year ends 09/30

Financial factors as of 2026-09-30 (2026Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-3.6%
TTM net income YoY16.7%
TTM EPS YoY38.8%
Revenue 3-yr CAGR-7.3%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-99.0%
Net margin-108.3%
FCF margin-67.9%
EBITDA margin-91.4%

Returns

ROE-94.2%
ROA-24.5%
ROIC (approx.)-106.7%
Asset turnover0.23x

Leverage & solvency

Liabilities / assets70.9%
Debt / equity0.00x
Current ratio3.78x
Interest coverage-4.43x

Cash quality & payout

Operating cash flow / net income0.62x
Accruals ratio-9.2%
Payout ratio—
Capex / revenue0.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-09-30FY20252025-09-30FY20242024-09-30FY20232023-09-30FY20222022-09-30
Income statement
Revenue$63.00M$65.32M$67.64M$79.20M$86.16M
R&D expense$88.55M$106.74M$131.48M$163.52M$164.52M
SG&A expense$36.84M$43.93M$57.85M$52.89M$45.48M
Operating income-$62.38M-$85.35M-$121.69M-$137.21M-$123.84M
Interest expense$14.07M$7.68M$10.94M$5.15M$0
Pretax income-$68.21M-$83.55M-$117.79M-$131.00M-$122.19M
Income tax$40,000-$1.66M-$1.74M$2.82M-$433,000
Net income-$68.25M-$81.89M-$116.05M-$133.82M-$121.75M
EBITDA-$57.60M-$80.76M-$119.36M-$134.84M-$120.87M
EPS (basic)-2.35-3.84-5.48-6.38-5.91
EPS (diluted)-2.35-3.84-5.48-6.38-5.91
Weighted avg. shares (diluted)29.00M21.34M21.16M20,96920,603
Balance sheet
Cash & equivalents$20.27M$32.30M$37.23M$85.39M$43.99M
Short-term investments$174.24M$156.57M$210.95M$284.52M$205.24M
Receivables$5.86M$6.88M$6.65M$8.61M$20.32M
Current assets$205.99M$204.34M$299.85M$422.79M$311.71M
PP&E, net$30.86M$35.40M$32.69M$11.92M$6.17M
Total assets$275.58M$280.73M$376.65M$462.27M$375.41M
Current liabilities$54.46M$48.55M$57.53M$62.79M$29.83M
Total liabilities$195.38M$216.01M$247.84M$245.54M$54.08M
Shareholders' equity$80.19M$64.72M$128.81M$216.74M$321.33M
Shares outstanding29.14M21.39M21.39M21.06M20.79M
Cash flow statement
Operating cash flow-$42.56M-$19.27M-$78.76M-$103.15M-$84.78M
Capital expenditure$206,000$12.90M$17.95M$9.06M$2.12M
Free cash flow-$42.77M-$32.17M-$96.71M-$112.21M-$86.91M
Investing cash flow-$17.18M$40.35M$58.23M-$53.58M$54.90M
Financing cash flow$47.72M-$26.62M-$27.63M$198.13M$20.03M
Depreciation & amortization$4.78M$4.59M$2.34M$2.37M$2.97M
Stock-based compensation$14.03M$18.57M$26.80M$28.22M$26.97M

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.